Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraarterial Bevacizumab for Glioblastoma Multiforme
NCT02285959Phase 1Unknown
- Sponsor
- Global Neurosciences Institute
- Start
- Jun 2014
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bevacizumab in glioblastoma multiforme (GBM), sponsored by Global Neurosciences Institute. Primary endpoint: Number of Participants with Adverse Events at 3 years. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02285959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02285959.